



Interpretation Guide



Marker (method)	AVISE CTD	AVISE Lupus	SLE Monitor	SLE Prognostic	AVISE APS	AVISE Vasculitis	Associated Disease	Sensitivity	Interpretation
EC4d (FACS)	●	●	●				Systemic Lupus Erythematosus (SLE)	46% ¹	Cell-Bound Complement Activation Products (CB-CAPs) EC4d & BC4d are measures of classical complement activation. CB-CAPs are primarily associated with SLE with 66% of patients having one or both CB-CAPs elevated ¹ . EC4d significantly correlates with fluctuations in SLE disease activity ² .
BC4d (FACS)	●	●						53% ¹	
PC4d (FACS)			●				SLE	20% ³	Elevated (>20 net MFI) Platelet Bound C4d (PC4d) is strongly associated with a recent (<5 years) history of thrombosis in SLE. SLE patients with persistently elevated PC4d have been shown to significantly associate with history of thrombosis and ischemic stroke ⁴ .
C3 (IT)			●				SLE	33% ¹	C3/C4 proteins are integral components of the complement system. Abnormally low concentrations of C3/C4 associate with SLE primarily with 44% of SLE patients having one or both proteins abnormally low.
C4 (IT)			●					32% ¹	
Anti-C1q IgG (ELISA)			●	●			Lupus Nephritis/disease activity	58% ⁵	Antibodies against the complement protein C1q are found in 58% of SLE patients with active lupus nephritis. Anti-C1q levels associate with renal activity ² . Low levels of anti-C1q antibodies have been found in up to 8% of patients with other diseases, such as infection and normal healthy individuals.
Anti-dsDNA IgG (ELISA and IFA)	●	●					SLE	33% ¹	Anti-dsDNA antibodies provide high positive predictive value due to high specificity for SLE. In the AVISE Lupus algorithm, patients are initially screened with an ELISA assay, and all patients testing positive are reflexed to Crithidia luciliae IFA testing for confirmation.
Anti-dsDNA (CIA)			●				SLE/disease activity	46% ^{25,26}	The anti-dsDNA by CIA method measures quantitative levels of anti-double stranded deoxyribonucleic acid with a superior correlation to disease activity compared to other methods.
Anti-Nuclear Antibodies IgG (ANA) (ELISA and IFA)	●	●					Lupus Nephritis	89% in SLE ¹	ANA has high negative predictive value for ruling out SLE due to its high sensitivity for SLE. However, ANA is found in many autoimmune disorders and a significant proportion of apparently healthy individuals.
Anti-Ribosomal P IgG (ELISA)				●			Neuropsychiatric Lupus	9% ⁶	Antibodies against ribosomal-P are highly specific for SLE and can be present in anti-dsDNA or anti-Sm negative patients. Anti-Ribosomal-P antibodies have been shown to associate with neuropsychiatric SLE manifestations.
Anti-Smith IgG (ELISA)	●	●					SLE	14% ¹	Anti-Smith antibodies are highly specific, but comparatively low sensitivity marker for SLE. One of the ACR criteria for SLE.
Marker (method)							Associated Disease	Sensitivity	Interpretation
Anti-CENP IgG (ELISA)	●	●					CREST Syndrome	20-60% ⁷	Antibodies to (CENP) protein-B are found in 20-60% of patients with CREST syndrome, a limited form of scleroderma.
Anti-Jo-1 IgG (ELISA)	●	●					Polymyositis/ Dermatomyositis (PM/DM)	20-30% ⁸	Marker to aid diagnosis of PM/DM. Found in about 25% of patients with PM/DM.
Anti-RNP70 IgG (ELISA)	●						Mixed Connective Tissue Disease (MCTD)	90% ⁹	RNP70 is a 70 kDa protein of the U1-snRNP complex. RNP70 antibodies are highly sensitive for MCTD.
Anti-Scl-70 IgG (ELISA)	●	●					Scleroderma	28-70% ¹⁰	Up to 70% of scleroderma patients are positive. Anti-Scl70 is highly specific for diffuse cutaneous scleroderma and associates with interstitial lung disease (ILD).
Anti-Ro52 IgG (CIA)	●						Myositis, SLE, Sjögren's Syndrome & Scleroderma	20-70% ¹¹	Ro52 antibodies are found in multiple autoimmune conditions. Anti-Ro52 has been shown to associate with interstitial lung disease (ILD) in patients with Sjögren's syndrome or scleroderma.
Anti-Ro60 IgG (CIA)	●						SLE, Sjögren's Syndrome, Myositis & Scleroderma	20-65% ¹¹	Ro60 antibodies are found in multiple autoimmune conditions. Anti-Ro60 is commonly found in both SLE and Sjögren's syndrome.
Anti-RNA Pol III IgG (ELISA)	●						Systemic Sclerosis	5-22% ¹²	Antibodies against RNA polymerase III are specific for systemic sclerosis often found in the absence of anti-Scl70 and anti-CENP antibodies. RNA Pol III antibodies associate with diffuse cutaneous scleroderma.
Anti-SS-B/La IgG (ELISA)	●	●					Sjögren's Syndrome	39% ¹	Anti-La antibodies are a low sensitivity but highly specific marker for Sjögren's Syndrome.
Anti-U1-RNP IgG (ELISA)	●						MCTD	95-99% ⁹	Anti-U1-RNP antibodies are highly sensitive for MCTD. Absence of anti-U1-RNP antibodies is used to rule out MCTD.
Anti-Histone IgG (ELISA)							Drug-Induced Lupus (DIL)	95% ¹³	Up to 95% of drug-induced lupus and 50% of SLE patients exhibit elevated levels of histone antibodies. Histone antibodies have also been found in RA, DM, and SS placing added importance on clinical presentation.

	Marker (method)	AVISE CID	AVISE Lupus	SLE Monitor	SLE Prognostic	AVISE APS	AVISE Vasculitis	Associated Disease	Sensitivity	Interpretation
RA Markers	Anti-Cyclic Citrullinated Peptide IgG (ELISA)	●	●					Rheumatoid Arthritis (RA)	70-90% ¹⁴	Antibodies to Cyclic Citrullinated Peptides (CCP) aid in the diagnosis of Rheumatoid Arthritis (RA). Anti-CCP antibodies are highly specific for RA. Anti-CCP is included in the AVISE Lupus algorithm to help with the differential diagnosis of RA vs. SLE.
	Anti-Carbamylated Protein IgG (ELISA)							RA	33% ¹⁵	Anti-CarP antibodies serve as a marker of more severe prognosis in RA, independent of anti-CCP or RF status. Studies have shown anti-CarP found in early RA associates with future erosive damage. The clinical significance of positive anti-CarP in the absence of RA has not been established.
	Rheumatoid Factor IgM & IgA (ELISA)	●						RA	70-90% ¹⁴	Quantitative measurement of IgM and IgA rheumatoid factors (RF) to aid in the diagnosis of rheumatoid arthritis. Presence of IgA RF isotype may be associated with more severe RA prognosis.
APS Markers	Marker (method)							Associated Disease	Sensitivity	Interpretation
	Anti-β2-Glycoprotein I IgG, IgM & IgA (ELISA)	●			●	●		Antiphospholipid Syndrome (APS)	45% ¹⁶	Antibodies to Beta 2 Glycoprotein 1 (β2 GP1) exhibit higher specificity than anti-cardiolipin assays. In 3-10% of APS patients, β2 GP1 antibodies may be the only positive test. Positive results should be confirmed after 12 weeks to ensure persistence of antibodies. IgA β2 GP1 antibodies are less common than IgG or IgM and can occur in isolation.
	Anti-Cardiolipin IgG, IgM & IgA (ELISA)	●			●	●		APS	97% ¹⁷	Antibodies to cardiolipin are present in SLE patients (30-40%) and APS. Prevalence of cardiolipin in APS is high but specificity for APS is lower than other anti-phospholipid antibodies. Positive results should be confirmed after 12 weeks.
	Anti-Phosphatidylserine /Prothrombin (PS/PT) IgM & IgG (ELISA)				●	●		APS	22-37% ³	Anti-PS/PT antibodies are markers for APS that have been found to significantly correlate with lupus anticoagulant (LAC) ¹⁷ . Unlike LAC, anti-PS/PT testing is unaffected by anti-coagulant therapy.
Thyroid Markers	Marker (method)							Associated Disease	Sensitivity	Interpretation
	Anti-Thyroglobulin IgG (ELISA)	●						Hashimoto's Thyroiditis & Graves' Disease	60-85% ¹⁸	Anti-thyroglobulin antibodies are found in 60-85% of patients with Hashimoto's thyroiditis and 30-80% of patients with Graves' disease.
	Anti-Thyroid Peroxidase IgG (ELISA)	●						Hashimoto's Thyroiditis & Graves' Disease	71-97% ¹⁸	Anti-thyroid peroxidase antibodies are found in > 90% of patients with Hashimoto's thyroiditis & 71-97% of patients with Graves' disease. Over 95% of thyroiditis patients have Thyroglobulin IgG and/or Thyroid peroxidase antibodies.
Vasculitis Markers	Marker (method)							Associated Disease	Sensitivity	Interpretation
	ANCA (IFA)						●	ANCA associated vasculitis	77% ²⁰	The c-ANCA pattern produces a granular cytoplasmic pattern with interlobular accentuation on ethanol fixed neutrophils. c-ANCA patterns are associated with necrotizing segmental glomerulonephritis and GPA ^{20,21} .
									85% ²⁰	The p-ANCA pattern produces perinuclear staining with or without nuclear extension. The p-ANCA pattern is commonly detected in patients with MPA and about 40% of patients with EGPA ^{21,25} .
	Anti-PR3 IgG (CIA)						●	Granulomatosis with Polyangiitis (GPA)	81% ²⁰	Anti-PR3 antibodies are primarily associated with GPA and to a lesser extent, found in MPA (10%) and EGPA ^{19,20} . However, anti-PR3 antibodies can also be seen in connective tissue disease, IBD, some infections, malignancy, and as a reaction to drugs. Therefore, results should be interpreted with care in light of the clinical findings and workup ²² .
	Anti-MPO IgG (CIA)						●	Microscopic Polyangiitis (MPA)	85% ²⁰	Anti-MPO antibodies are primarily associated with MPA and to a lesser extent, found in GPA (6%) and EGPA ^{19,20} . However, anti-MPO antibodies can also be seen in connective tissue disease, IBD, some infections, malignancy, and as a reaction to drugs. Therefore, results should be interpreted with care in light of the clinical findings and workup ²² .
Anti-GBM IgG (CIA)						●	Goodpasture's Syndrome (GPS)	96% ²³	Anti-GBM antibodies are often associated with Goodpasture's disease and anti-GBM nephritis ²³ . A significant proportion of patients with anti-GBM disease are also positive for ANCA.	

AVISE HCQ

A test to aid in assessing adherence to HCQ and individual exposure to HCQ as measured in whole blood.

HCQ Level	Interpretation & Consideration
Therapeutic (>1000 ng/mL)	Level associated with clinical efficacy. HCQ is likely absorbed effectively.
Sub-therapeutic (200-1000 ng/mL)	Patient could be partially adherent to therapy. Patients with HCQ lower than 1000 ng/mL can be at greater risk for disease flare.
Underexposed (<200 ng/ml)	Patient is likely non-adherent to HCQ therapy.

AVISE MTX

A test to aid in assessing adherence to MTX and individual exposure to active MTX metabolites in red blood cells.

MTXPG Level	Interpretation & Consideration
Therapeutic (>60 nmol/L)	Patient is metabolizing MTX effectively. Level is consistent with clinical efficacy.
Intermediate (20-60 nmol/L)	Patient may need more exposure to MTX.
Sub-therapeutic (<20 nmol/L)	Patient may not be metabolizing MTX effectively or patient may be non-adherent with therapy.

Methodology Definitions:

FACS: Fluorescence-Activated Cell Sorting
 IFA: Immunofluorescence
 ELISA: Enzyme-Linked Immunosorbent Assay
 CIA: Chemiluminescent Immunoassay
 IT: Immunoturbidimetry


References:

- Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. *Lupus Sci Med.* 2014;1(1):e000056. doi:10.1136/lupus-2014-000056
- Buyon J, Furie R, Putterman C, et al. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. *Lupus Sci Med.* 2016;3(1):1-8. doi:10.1136/lupus-2016-000165
- Petri MA, Conklin J, O'Malley T, Dervieux T. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. *Lupus Sci Med.* Published online 2019;6-11. doi:10.1136/lupus-2019-000318
- Kao AH, McBurney CA, Sattar A, et al. Relation of Platelet C4d with All-Cause Mortality and Ischemic Stroke in Patients with Systemic Lupus Erythematosus. *Transl Stroke Res.* 2014;5(4):510-518. doi:10.1007/s12975-013-0295-9
- Yin Y, Wu X, Shan G, Zhang X. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: A meta-analysis. *Lupus.* 2012;21(10):1088-1097. doi:10.1177/0961203312451202
- Hanly JG, Urowitz MB, Su L, Romero-Diaz J. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus *Ann Rheum Dis.* 2011;70(12):2240. doi:10.1136/ard.2010.148502corr1
- Russo K, Hoch S, Dima C, Varga J, Teodorescu M. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. *J Rheumatol.* 2000;27(1):142-148
- Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-Jo-1 antibodies. *Autoimmunity.* 2005;38(1):73-78. doi:10.1080/08916930400022640
- Hoffman R.W., Greidinger E.L. (2002) Mixed Connective Tissue Disease. In: Tsokos G.C. (eds) *Modern Therapeutics in Rheumatic Diseases.* Humana Press, Totowa, NJ. Doi:10.1007/978-1-59259-239-5_23
- Basu D, Reveille JD. *Anti-scl-70.* *Autoimmunity.* 2005;38(1):65-72. doi:10.1080/08916930400022947
- Robbins A, et al. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases. *Front Immunol.* 2019;10:444. doi: 10.3389/fimmu.2019.00444
- Maes L, et al. Anti-PL/Sci-100 and RNA-Pol III antibodies in scleroderma. *Clin Chim Acta.* 2010; 411(13-14): 965-71. doi: 10.1016/j.cca.2010.03.018
- Dalle Vedove C, Simon JC, Girolomoni G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF α agents. *J Dtsch Dermatol Ges.* 2012;10(12):889-897. doi:10.1111/j.1610-0387.2012.08000.x
- Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. *Arthritis Rheum.* 2003;48(10):2741-2749. doi:10.1002/art.11223
- Truchetet ME, et al. Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiological outcome. *Arthritis & Rheumatology.* 2017;69(12): 2292-2302. doi: 10.1002/art.40237
- Monica Galli, Davide Luciani, Guido Bertolini, Tiziano Barbui; Anti- β 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. *Blood.* 2003; 102 (8): 2717–2723. doi: 10.1182/blood-2002-11-3334
- Akhter E, Shums Z, Norman GL, Binder W, Fang H, Petri M. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. *J Rheumatol.* 2013;40(3):282-286. doi:10.3899/jrheum.120084
- Engler H, Riesen WF, Keller B. Anti-thyroid peroxidase (anti-TPO) antibodies in thyroid diseases, non-thyroidal illness and controls. Clinical validity of a new commercial method for detection of anti-TPO (thyroid microsomal) autoantibodies. *Clin Chim Acta.* 1994;225(2):123-136. doi:10.1016/0009-8981(94)90040-x
- Mahler M, Radice A, Yang W, et al. Clinica Chimica Acta Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. *Clin Chim Acta.* 2012;413(7-8):719-726. doi:10.1016/j.cca.2012.01.004
- Damoiseaux J, Csernok E, Rasmussen N, et al. Detection of antineutrophil cytoplasmic antibodies (ANCA): A multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. *Ann Rheum Dis.* 2017;76(4):647-653. doi:10.1136/annrheumdis-2016-209507
- Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). *Am J Clin Pathol.* 999;111(4):507-13. doi: 10.1093/ajcp/111.4.507
- Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. *BMJ.* 2020;368(March):1-16. doi:10.1136/bmj.m421
- Mahler M, Radice A, Sinico RA, et al. Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study. 2012;3(May 2011):24
- Bossuyt X, Tervaert JW, Arimura Y, et al. Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. *Nat Rev Rheum.* 2017;13:683-692. doi: 10.1038/nrrheum.2017.140
- Merrill J, Petri M, Buyon J, et al. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. *Lupus Science & Medicine.* 2018.
- Mahler M, Bentow C, O'Malley T, et al. Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus. *J Immunol Res.* 2017;2017:1720902.

A deeper look at the AVISE® Lupus two tier algorithm

TIER 1

Tier 1 criteria is highly specific for SLE



If Tier 1 is Negative move to Tier 2

TIER 2

When levels are elevated	Impact on Index
ANA Component ELISA	↑ +
CB-CAPs Component EC4d & BC4d	↑ +
Specificity Component Anti-CCP Anti-SS-B/La Anti-CENP Anti-Scl-70 Anti-Jo-1	↓ -



Tier 2 generates an index value based on the following components

- Level of ANA ELISA result (negative, positive, strong positive)
- Measurement of classical complement activation (CB-CAPs component) measured on a continuous scale
- Presence of auto-antibodies specific to other autoimmune CTDs


AVISE® CTD and AVISE Lupus result report

	Order ID	739814	Specimen Collected	01/15/2022	Patient	Sample, Susan S Gender - DOB Formula - 01/01/1908
	Provider	Esagen Provider MD	Received	01/18/2022		
	Test Order Created	01/18/2022	Identifer Received			
	Reported	01/20/2022	Esagen ID	541163		

AVISE CTD Test Report

AVISE Lupus Result: Tier 1 Positive

The result for the AVISE Lupus algorithm is featured first, plotted along a gradient of increasing likelihood for presence of SLE



Analytes included in Tier 1 and Tier 2 along with respective assessments are reported in two distinct sections

Tier 1 Analytes	Value	Interpretation	Reference Range	Tier 1 Assessment
Anti-dsDNA IgG	413.00 IU/mL	POSITIVE	<201 - Negative 201-302 - Equivocal ≥302 - Positive	Positive
Confirmation by Crithidia luciliae				
Anti-Smith IgG	1.0 U/mL	Negative	<7 - Negative 7-10 - Equivocal >10 - Positive	
CB-CAP: EC4d - Erythrocyte-bound C4d	8 Net MFI	Negative	<15 - Negative 15-75 - Positive >75 - Strong Positive	
CB-CAP: BC4d - B-lymphocyte-bound C4d	125 Net MFI	POSITIVE	<61 - Negative 61-200 - Positive >200 - Strong Positive	
<p>Note: The Tier 1 result is associated with an increased likelihood of SLE and is the product of the following analyte values meeting the Tier 1 criteria: Anti-dsDNA, confirmed by Crithidia IFA</p>				

Tier 2 Analytes	Value	Interpretation	Reference Range	Tier 2 Assessment
ANA IgG	>150 Units	STRONG POSITIVE	<20 - Negative 20-60 - Positive ≥60 - Strong Positive	Not assessed due to Tier 1 Positive
CB-CAP: EC4d - Erythrocyte-bound C4d	8 Net MFI	Negative	<15 - Negative 15-75 - Positive >75 - Strong Positive	
CB-CAP: BC4d - B-lymphocyte-bound C4d	125 Net MFI	POSITIVE	<61 - Negative 61-200 - Positive >200 - Strong Positive	
Anti-SS-B/La IgG	1.0 U/mL	Negative	<7 - Negative 7-10 - Equivocal >10 - Positive	
Anti-Scl-70 IgG	1.0 U/mL	Negative	<7 - Negative 7-10 - Equivocal >10 - Positive	
Anti-Centromere Protein B (CENP) IgG	1.0 U/mL	Negative	<7 - Negative 7-10 - Equivocal >10 - Positive	
Anti-Jo-1 IgG	1.0 U/mL	Negative	<7 - Negative 7-10 - Equivocal >10 - Positive	
Anti-CCP IgG	1.0 U/mL	Negative	<7 - Negative 7-10 - Equivocal >10 - Positive	
<p>Note:</p>				

Approved by: Richard Sadrin, MD

Date: 01-20-2022

Results were obtained using flow cytometry for complement C4d fragment bound to erythrocytes (EC4d) and B-lymphocytes (BC4d). Autoantibodies were determined using solid phase immunoassays. ANA was determined by indirect immunofluorescence and solid phase assays. ANA by solid phase assay was used for titer index calculation. In a study of 794 subjects comprising 384 SLE patients, 283 patients with other rheumatic diseases and 200 normal healthy controls, positivity for Tier 1 markers (anti-dsDNA, confirmed using Crithidia, anti-Smith or elevated EC4d and BC4d) was associated with a sensitivity of 46% and a specificity of 97%. Among the 448 subjects negative in Tier 1, a positive index score composite of ANA (by ELISA), EC4d/BC4d and positivity for anti-citrullinated peptide antibodies, SS-B/La, CENP, Jo-1 or Scl-70 resulted in sensitivity of 62% for SLE and specificity of 28%. Two tier combination yielded 80% sensitivity for SLE and 80% specificity for other rheumatic diseases (80% specificity vs. healthy).

AVISE® CTD and AVISE Lupus page 2

Details for ANA (HEp-2) are at the top of the page including any observed nuclear and cytoplasmic patterns

Far left column identifies positive(+) and strong positive(++) interpretations for each analyte

SLE-Associated Analytes		Value	Interpretation	Reference Range
++ ANA IgG		>150 Units	STRONG POSITIVE	EUSA: <25 - Negative 25-60 - Positive ≥60 - Strong Positive
+ ANA by HEp-2	Titre:	1:320	POSITIVE	IFA: <1:20 - Negative ≥1:20 - Positive
Nuclear Pattern: Homogeneous Cytoplasmic Pattern: Observed				
+ Anti-dsDNA IgG		413.00 IU/mL	POSITIVE	EUSA: <201 - Negative 201-402 - Equivocal ≥402 - Positive
+ Anti-dsDNA by Crithidia (confirmatory)			POSITIVE	IFA: Negative
Anti-Smith IgG		1.0 U/mL	Negative	EUSA: <7 - Negative 7-30 - Equivocal ≥30 - Positive
CB-CAP: EC4d - Erythrocyte-bound C4d		8 Net MFI	Negative	FAIS: <15 - Negative 15-75 - Positive ≥75 - Strong Positive
+ CB-CAP: BC4d - B-lymphocyte-bound C4d		125 Net MFI	POSITIVE	FAIS: <61 - Negative 61-200 - Positive ≥200 - Strong Positive
Other Autoimmune Disease Auto-Antibodies		Value	Interpretation	Reference Range
Anti-UJRNP IgG		3.0 U/mL	Negative	EUSA: <5 - Negative 5-10 - Equivocal ≥10 - Positive
Anti-RNP70 IgG		1.0 U/mL	Negative	EUSA: <7 - Negative 7-10 - Equivocal ≥10 - Positive
Anti-Ro52 IgG		5.0 CU	Negative	DA: <20 - Negative ≥20 - Positive
Anti-Ro60 IgG		3.0 CU	Negative	DA: <20 - Negative ≥20 - Positive
Anti-SS-B/La IgG		1.0 U/mL	Negative	EUSA: <7 - Negative 7-10 - Equivocal ≥10 - Positive
Anti-Scl-70 IgG		1.0 U/mL	Negative	EUSA: <7 - Negative 7-10 - Equivocal ≥10 - Positive
Anti-RNA Pol III IgG		10.00 Units	Negative	EUSA: <25 - Negative 25 - 80 - Equivocal ≥80 - Strong Positive
Anti-Centromere Protein B [CCP] IgG		1.0 U/mL	Negative	EUSA: <7 - Negative 7-10 - Equivocal ≥10 - Positive
Anti-Jo-1 IgG		1.0 U/mL	Negative	EUSA: <7 - Negative 7-10 - Equivocal ≥10 - Positive
Rheumatoid Arthritis Auto-Antibodies		Value	Interpretation	Reference Range
Rheumatoid Factor IgM		2.0 IU/mL	Negative	EUSA: <3.5 - Negative 3.5-5 - Equivocal ≥5 - Positive
Rheumatoid Factor IgA		1.0 IU/mL	Negative	EUSA: <14 - Negative 14-20 - Equivocal ≥20 - Positive
Anti-CCP IgG		1.0 U/mL	Negative	EUSA: <7 - Negative 7-10 - Equivocal ≥10 - Positive
Antiphospholipid Syndrome Auto-Antibodies		Value	Interpretation	Reference Range
Anti-Cardiolipin IgM		2.0 U/mL	Negative	EUSA: <10 - Negative 10-40 - Weak Positive ≥40 - Positive
Anti-Cardiolipin IgG		4.0 U/mL	Negative	EUSA: <10 - Negative 10-40 - Weak Positive ≥40 - Positive
Anti-β2 Glycoprotein 1 IgM		3.0 U/mL	Negative	EUSA: <7 - Negative 7-10 - Equivocal ≥10 - Positive
Anti-β2 Glycoprotein 1 IgG		2.0 U/mL	Negative	EUSA: <7 - Negative 7-10 - Equivocal ≥10 - Positive
Thyroid Auto-Antibodies		Value	Interpretation	Reference Range
Anti-Thyroglobulin IgG		<12 IU/mL	Negative	EUSA: <40 - Negative 40-60 - Equivocal ≥60 - Positive
Anti-Thyroid Peroxidase IgG		<4 IU/mL	Negative	EUSA: <25 - Negative 25-35 - Equivocal ≥35 - Positive
Notes:				
References				
<small>1) Kallunki E, et al. Measurement of CB-C4d enhances diagnostic performance in SLE. Arthritis Rheum. 2011 Dec;54(12):4040-7. 2) Wallace DJ, et al. Systemic lupus erythematosus and primary biliary cirrhosis: can be distinguished by testing for cell-bound complement activation products. Lupus 24(10), 2015. doi:10.1177/0961203415580327. 3) Petzmann C, et al. CB-CAPs in SLE: comparison with anti-dsDNA and modified complement measurements. Lupus 24(10), 2015. doi:10.1177/0961203415580327 </small>				
<small>Page 2 of 2</small>				
		1861 Liberty Way, Vista CA 92081 CLIA# 08D1078048 CAP# 7201061 NYSDOH PPS# 8888		Laboratory Director: Richard Salton, MD R. Harper Summers, MD
		Provider Relations: 888.452.1522 AVISE and the AVISE and Exagen logos are registered trademarks of Exagen Inc. ©2022 All Rights Reserved		
<small>This test is used for clinical purposes, though results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. It should not be regarded as investigational or for research. It has not been cleared or approved by the FDA. Exagen is regulated under CLIA as qualified to perform high-complexity testing. 8/11/22 2/22/22</small>				

Notes provide clarification and summary statements

Provider Relations: 888.452.1522

Call Provider Relations with any questions or to arrange for a clinical consultation

AVISE®



Exagen, AVISE and the Exagen and AVISE logo are registered trademarks of Exagen Inc.
© Copyright 2022 Exagen Inc. All rights reserved. SA1123 (08/22)

www.AviseTest.com | 888.452.1522

Exagen®
Patient Focused. Discovery Driven.